Authors

Latest:

Dr. Diamond on the Ability to Test Urine for BRAF Mutations

Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis that examined the detection of BRAF mutations in urine and plasma cell-free DNA in patients with Langerhans Cell Histiocytosis(LCH) and Erdheim-Chester Disease (ECD) who have a BRAFV600E mutation

Elias J. Jabbour, MD, MD Anderson

Latest:

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Elias Jabbour, MD

Latest:

Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD

Dr Jabbour discusses data that support the continued investigation of olverembatinib in patients with heavily pretreated chronic-phase CML.

Elias Jabbour, MD, MD Anderson

Elias Jabbour, MD, MD Anderson Cancer Center

Latest:

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Elias Obeid, MD, MPH

Latest:

Dr. Obeid on the KATHERINE Trial in HER2-Positive Breast Cancer

Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.

Elihu Estey, MD, University of Washington School of Medicine Seattle

Elihu H. Estey, MD

Latest:

Dr. Estey Discusses the FDA Approval Process

Elihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, discusses a potential change to the FDA approval process as it relates to Mylotarg (gemtuzumab ozogamicin).

Elisa K. Chan, MD

Latest:

Dr. Chan on Improving Mammography Screening Rates With Signed Letters

Elisa K. Chan, MD, discusses improving mammography screening rates with signed letters from physicians. Chan worked for the BC Cancer Agency during the study.

Elisa Krill-Jackson, MD

Latest:

Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2+ Breast Cancer

Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.

Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute

Latest:

Practical Application of PARP Inhibitors in Metastatic CRPC

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Elisabeth Weiss, MD

Latest:

Diffusion-Weighted MRI Studies Explored at VCU Massey Cancer Center

The Department of Radiation Oncology at Virginia Commonwealth University Massey Cancer Center has long been at the forefront worldwide in the development of various radiation therapy technologies that are now considered standard and have become widely available.

Elisavet Paplomata, MD

Latest:

Dr. Paplomata on the Role of Tucatinib/Trastuzumab/Capecitabine in HER2+ Metastatic Breast Cancer

Elisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

Elissa Engel, MD

Latest:

Dr. Engel on the Future of Eltrombopag in HIV-Related Thrombocytopenia

Elissa Engel, MD, pediatric resident, University of South Florida, discusses the future of eltrombopag (Promacta) in HIV-related thrombocytopenia.

Elizabeth A. Guancial, MD

Latest:

Androgen Deprivation Therapy and Cardiovascular Risk in Prostate Cancer

Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association

Elizabeth A. McDonald

Latest:

Preparing for the Job Search

Before you even contact a physician recruiter, respond to a posted position, or network your contacts for leads, you need to know which factors are important to you in finding the position that meets your goals

Elizabeth A. Mittendorf, MD, PhD

Latest:

Dr. Mittendorf on QoL With Neoadjuvant Atezolizumab/Chemo in Early TNBC

Elizabeth A. Mittendorf, MD, PhD, discusses patient-reported quality of life associated with neoadjuvant atezolizumab plus chemotherapy in early triple-negative breast cancer.

Elizabeth Barton

Latest:

Listen Up: Speech Recognition Technology Spreads in EHR Era

Medical records have changed significantly in the past decade, with powerful servers and digital archives replacing rooms jammed with filing cabinets and folders stuffed with hand-scribbled notes.

Elizabeth Blasiak, RN, MSN

Latest:

Elizabeth Blasiak Discusses the ONS Congress

Elizabeth Blasiak on the Significance of the ONS Congress

Elizabeth Bossart, PhD

Latest:

A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures